Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17250
Corporate User License Price USD 750
Corporate User License Price INR 51750
Site License Price USD 500
Site License Price INR 34500
Request a Quote

Report Title

OSE Immunotherapeutics (OSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

OSE Immunotherapeutics (OSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

OSE Immunotherapeutics (OSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

OSE Immunotherapeutics (OSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company's memopi technology is employed in studying the development of treatments for ovarian, colon and breast cancer. It provides products such as tedopi and effi-7. OSE's Effi-7 is in preclinical development and targets autoimmune diseases and transplantation. OSE's tedopi stimulates cytotoxic killer T cells and relearns them to detect cancer cells to eliminate them. The company offers pipeline products such as OSE-172, OSE-703, FR104, 0SE-127. It markets its products through its distribution network. OSE is headquartered in Nantes, France.

OSE Immunotherapeutics (OSE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OSE Immunotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

OSE Pharma to Raise USD4.1 Million in Venture Financing Round 12

Partnerships 13

OSE Immunotherapeutics Enters into Agreement with GERCOR 13

OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 14

Selexis Enters into Agreement with OSE Immunotherapeutics 15

OSE Pharma Partners with Effimune 16

Merger 17

Effimune and OSE Pharma Merge 17

Licensing Agreements 18

Boehringer Ingelheim Enters into Licensing Agreement with OSE Immunotherapeutics 18

OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 19

OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-172 20

OSE Immunotherapeutics Enters into Licensing Agreement with Selexis 21

OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 22

Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 23

OSE Pharma Enters into Licensing Agreement with RAFA Labs 24

OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-703 25

Equity Offering 26

OSE Pharma Raises USD23 Million in IPO 26

Acquisition 27

OSE Pharma Acquires OPI, Pharma Company 27

OSE Immunotherapeutics-Key Competitors 28

OSE Immunotherapeutics-Key Employees 29

OSE Immunotherapeutics-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Sep 06, 2018: OSE Immunotherapeutics announces first-half 2018 financial results 31

Mar 28, 2018: OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products 33

Sep 07, 2017: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio 35

Corporate Communications 37

Apr 12, 2018: OSE Immunotherapeutics Announces Evolution in Company's Board of Directors and Management 37

Jan 03, 2018: OSE Immunotherapeutics Announces Appointment of Gerard Tardy as Chairman of Company's Board of Directors 39

Legal and Regulatory 40

Apr 23, 2018: OSE Immunotherapeutics Receives the Euronext Tech40 Label 40

Product News 41

12/14/2017: OSE Immunotherapeutics Receives a Grant from French Government Program "Fonds Unique Interministeriel" to Explore New Cytotoxic Antibodies 41

Clinical Trials 42

May 07, 2018: OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas 42

Dec 19, 2017: OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases 43

Jun 21, 2017: OSE Immunotherapeutics Receives Payment of EUR2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127 44

Jun 15, 2017: OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies Conference 45

Other Significant Developments 46

Jun 13, 2018: OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OSE Immunotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OSE Immunotherapeutics, Deals By Therapy Area, 2012 to YTD 2018 9

OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

OSE Pharma to Raise USD4.1 Million in Venture Financing Round 12

OSE Immunotherapeutics Enters into Agreement with GERCOR 13

OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 14

Selexis Enters into Agreement with OSE Immunotherapeutics 15

OSE Pharma Partners with Effimune 16

Effimune and OSE Pharma Merge 17

Boehringer Ingelheim Enters into Licensing Agreement with OSE Immunotherapeutics 18

OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 19

OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-172 20

OSE Immunotherapeutics Enters into Licensing Agreement with Selexis 21

OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 22

Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 23

OSE Pharma Enters into Licensing Agreement with RAFA Labs 24

OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-703 25

OSE Pharma Raises USD23 Million in IPO 26

OSE Pharma Acquires OPI, Pharma Company 27

OSE Immunotherapeutics, Key Competitors 28

OSE Immunotherapeutics, Key Employees 29

OSE Immunotherapeutics, Other Locations 30

OSE Immunotherapeutics, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

OSE Immunotherapeutics, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person